Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04438824 · ClinicalTrials.gov registry record · Phase 2
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
A Phase 2 study of Well-differentiated/Dedifferentiated Liposarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 7
- Study locations
NCT04438824 is a Phase 2 study of Well-differentiated/Dedifferentiated Liposarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 42 participants. The trial reports 7 study locations across 2 states.
The verdict
NCT04438824, a Phase 2 study of Well-differentiated/Dedifferentiated Liposarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma. "Funding Source - FDA OOPD"
Conditions Studied
Interventions
- DRUG Palbociclib
- DRUG INCMGA00012
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04438824
The ClinicalTrials.gov registry entry for NCT04438824 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Well-differentiated/Dedifferentiated Liposarcoma appearing as the primary indexed condition, and to 2 interventions - of which Palbociclib is the first listed.
NCT04438824 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04438824 about?
NCT04438824 is a clinical study titled "Palbociclib and INCMGA00012 in People With Advanced Liposarcoma". The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma. "Funding Source - FDA OOPD"
What is the current status of trial NCT04438824?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2020-06-17. Estimated completion is 2026-06.
What conditions does trial NCT04438824 study?
This clinical trial studies the following conditions: Well-differentiated/Dedifferentiated Liposarcoma.
What interventions are being tested in trial NCT04438824?
The interventions under investigation include: Palbociclib (DRUG), INCMGA00012 (DRUG).
Who is sponsoring clinical trial NCT04438824?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04438824 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.